Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of LIMA Association in Type 2 Diabetes
NCT03766750Phase 3Withdrawn
- Sponsor
- EMS
- Start
- Dec 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of linagliptin and dapagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by EMS. Primary endpoint: Reduction of glycated hemoglobin levels at 120 days. Planned start Dec 2021; status: withdrawn.
02
Drugs
linagliptindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03766750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03766750.